Biogen Pharmachem Industries L

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SGFIN.BO has a market cap of 22B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SGFIN.BO trades at ₹390.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SGFIN.BO's P/E ratio is 22.24. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SGFIN.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SGFIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SGFIN.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, AQFINTECH.BO has a market cap of 19.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while AQFINTECH.BO trades at ₹1,226.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas AQFINTECH.BO's P/E ratio is 1095.40. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to AQFINTECH.BO's ROE of +0.15%. Regarding short-term risk, BIOGEN.BO is less volatile compared to AQFINTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check AQFINTECH.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, LKPFIN.BO has a market cap of 12.5B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while LKPFIN.BO trades at ₹990.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas LKPFIN.BO's P/E ratio is -628.46. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to LKPFIN.BO's ROE of -0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to LKPFIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check LKPFIN.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, MASTERTR.BO has a market cap of 10.8B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while MASTERTR.BO trades at ₹89.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas MASTERTR.BO's P/E ratio is 9.01. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to MASTERTR.BO's ROE of +0.17%. Regarding short-term risk, BIOGEN.BO is less volatile compared to MASTERTR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check MASTERTR.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SYSTMTXC.BO has a market cap of 10.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SYSTMTXC.BO trades at ₹75.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SYSTMTXC.BO's P/E ratio is 36.34. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SYSTMTXC.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SYSTMTXC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SYSTMTXC.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, AKCAPIT.BO has a market cap of 10.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while AKCAPIT.BO trades at ₹1,539.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas AKCAPIT.BO's P/E ratio is 9.95. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to AKCAPIT.BO's ROE of +0.10%. Regarding short-term risk, BIOGEN.BO is less volatile compared to AKCAPIT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check AKCAPIT.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, INDPRUD.BO has a market cap of 8.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while INDPRUD.BO trades at ₹5,273.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas INDPRUD.BO's P/E ratio is 13.41. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to INDPRUD.BO's ROE of +0.08%. Regarding short-term risk, BIOGEN.BO is less volatile compared to INDPRUD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check INDPRUD.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, GCSL.BO has a market cap of 7.9B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while GCSL.BO trades at ₹347.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas GCSL.BO's P/E ratio is -58.27. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to GCSL.BO's ROE of -0.02%. Regarding short-term risk, BIOGEN.BO is more volatile compared to GCSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check GCSL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ARYAMAN.BO has a market cap of 7.9B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ARYAMAN.BO trades at ₹639.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ARYAMAN.BO's P/E ratio is 18.28. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ARYAMAN.BO's ROE of +0.23%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ARYAMAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARYAMAN.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ARYACAPM.BO has a market cap of 5.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ARYACAPM.BO trades at ₹425.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ARYACAPM.BO's P/E ratio is 15.54. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ARYACAPM.BO's ROE of +0.27%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ARYACAPM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARYACAPM.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SRAMSET.BO has a market cap of 5.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SRAMSET.BO trades at ₹317.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SRAMSET.BO's P/E ratio is -27.76. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SRAMSET.BO's ROE of -0.19%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SRAMSET.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SRAMSET.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, KIRANVYPAR.BO has a market cap of 5B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while KIRANVYPAR.BO trades at ₹178.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas KIRANVYPAR.BO's P/E ratio is 281.54. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to KIRANVYPAR.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is less volatile compared to KIRANVYPAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check KIRANVYPAR.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, UCIL.BO has a market cap of 4.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while UCIL.BO trades at ₹96.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas UCIL.BO's P/E ratio is 4.39. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to UCIL.BO's ROE of +1.04%. Regarding short-term risk, BIOGEN.BO is more volatile compared to UCIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check UCIL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, OIVL.BO has a market cap of 3.8B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while OIVL.BO trades at ₹7.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas OIVL.BO's P/E ratio is -1.15. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to OIVL.BO's ROE of +0.98%. Regarding short-term risk, BIOGEN.BO is less volatile compared to OIVL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check OIVL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, HAMPTON.BO has a market cap of 3.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while HAMPTON.BO trades at ₹11.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas HAMPTON.BO's P/E ratio is -1169.00. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to HAMPTON.BO's ROE of -0.09%. Regarding short-term risk, BIOGEN.BO is less volatile compared to HAMPTON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check HAMPTON.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, IMCAP.BO has a market cap of 3.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while IMCAP.BO trades at ₹914.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas IMCAP.BO's P/E ratio is 229.89. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to IMCAP.BO's ROE of +0.29%. Regarding short-term risk, BIOGEN.BO is less volatile compared to IMCAP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check IMCAP.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ALSL.BO has a market cap of 2.8B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ALSL.BO trades at ₹57.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ALSL.BO's P/E ratio is 42.25. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ALSL.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ALSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ALSL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, QUESTCAP.BO has a market cap of 2.7B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while QUESTCAP.BO trades at ₹263.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas QUESTCAP.BO's P/E ratio is 6.83. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to QUESTCAP.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to QUESTCAP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check QUESTCAP.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, NIDHGRN.BO has a market cap of 2.5B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while NIDHGRN.BO trades at ₹318.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas NIDHGRN.BO's P/E ratio is 70.51. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to NIDHGRN.BO's ROE of +0.31%. Regarding short-term risk, BIOGEN.BO is less volatile compared to NIDHGRN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check NIDHGRN.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SHARDUL.BO has a market cap of 2.5B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SHARDUL.BO trades at ₹29.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SHARDUL.BO's P/E ratio is -4.51. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SHARDUL.BO's ROE of -0.07%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SHARDUL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SHARDUL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, PROFINC.BO has a market cap of 2.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while PROFINC.BO trades at ₹3.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas PROFINC.BO's P/E ratio is 16.63. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to PROFINC.BO's ROE of +0.22%. Regarding short-term risk, BIOGEN.BO is less volatile compared to PROFINC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check PROFINC.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, VISCO.BO has a market cap of 2.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while VISCO.BO trades at ₹92.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas VISCO.BO's P/E ratio is 7.50. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to VISCO.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is less volatile compared to VISCO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check VISCO.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SODFC.BO has a market cap of 2.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SODFC.BO trades at ₹124.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SODFC.BO's P/E ratio is -26.16. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SODFC.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SODFC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SODFC.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, REGENCY.BO has a market cap of 2.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while REGENCY.BO trades at ₹28.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas REGENCY.BO's P/E ratio is 22.28. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to REGENCY.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is less volatile compared to REGENCY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check REGENCY.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, PHCAP.BO has a market cap of 1.8B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while PHCAP.BO trades at ₹584.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas PHCAP.BO's P/E ratio is -94.86. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to PHCAP.BO's ROE of -0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to PHCAP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check PHCAP.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, JHACC.BO has a market cap of 1.6B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while JHACC.BO trades at ₹165.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas JHACC.BO's P/E ratio is 126.83. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to JHACC.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to JHACC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check JHACC.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, CGFL.BO has a market cap of 1.6B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while CGFL.BO trades at ₹31.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas CGFL.BO's P/E ratio is 17.16. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to CGFL.BO's ROE of +0.14%. Regarding short-term risk, BIOGEN.BO is less volatile compared to CGFL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check CGFL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, TAMBOLIIN.BO has a market cap of 1.5B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while TAMBOLIIN.BO trades at ₹155.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas TAMBOLIIN.BO's P/E ratio is 18.71. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to TAMBOLIIN.BO's ROE of +0.07%. Regarding short-term risk, BIOGEN.BO is less volatile compared to TAMBOLIIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check TAMBOLIIN.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, UPSURGE.BO has a market cap of 1.5B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while UPSURGE.BO trades at ₹75.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas UPSURGE.BO's P/E ratio is 18.14. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to UPSURGE.BO's ROE of +0.09%. Regarding short-term risk, BIOGEN.BO is less volatile compared to UPSURGE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check UPSURGE.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ARIHCAPM.BO has a market cap of 1.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ARIHCAPM.BO trades at ₹68.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ARIHCAPM.BO's P/E ratio is 8.17. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ARIHCAPM.BO's ROE of +0.14%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ARIHCAPM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARIHCAPM.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, PMCFIN.BO has a market cap of 1.4B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while PMCFIN.BO trades at ₹1.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas PMCFIN.BO's P/E ratio is 27.29. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to PMCFIN.BO's ROE of +0.05%. Regarding short-term risk, BIOGEN.BO is less volatile compared to PMCFIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check PMCFIN.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ESCORP.BO has a market cap of 1.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ESCORP.BO trades at ₹115.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ESCORP.BO's P/E ratio is 27.83. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ESCORP.BO's ROE of +0.18%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ESCORP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ESCORP.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ASSAMENT.BO has a market cap of 1.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ASSAMENT.BO trades at ₹835.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ASSAMENT.BO's P/E ratio is 27.19. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ASSAMENT.BO's ROE of +0.07%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ASSAMENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ASSAMENT.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, DHARNI.BO has a market cap of 1.3B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while DHARNI.BO trades at ₹61.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas DHARNI.BO's P/E ratio is 28.96. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to DHARNI.BO's ROE of +0.19%. Regarding short-term risk, BIOGEN.BO is more volatile compared to DHARNI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check DHARNI.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, LKPSEC.BO has a market cap of 1.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while LKPSEC.BO trades at ₹14.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas LKPSEC.BO's P/E ratio is 11.40. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to LKPSEC.BO's ROE of +0.12%. Regarding short-term risk, BIOGEN.BO is less volatile compared to LKPSEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check LKPSEC.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, PIONRINV.BO has a market cap of 1.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while PIONRINV.BO trades at ₹97.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas PIONRINV.BO's P/E ratio is 7.11. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to PIONRINV.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is less volatile compared to PIONRINV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check PIONRINV.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, AARNAV.BO has a market cap of 1.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while AARNAV.BO trades at ₹27.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas AARNAV.BO's P/E ratio is 16.46. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to AARNAV.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to AARNAV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check AARNAV.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SCL.BO has a market cap of 1.2B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SCL.BO trades at ₹0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SCL.BO's P/E ratio is 4.40. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SCL.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SCL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, VISTARAMAR.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while VISTARAMAR.BO trades at ₹197.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas VISTARAMAR.BO's P/E ratio is -65.21. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to VISTARAMAR.BO's ROE of +0.16%. Regarding short-term risk, BIOGEN.BO is less volatile compared to VISTARAMAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check VISTARAMAR.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, MUNCAPM.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while MUNCAPM.BO trades at ₹123.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas MUNCAPM.BO's P/E ratio is 352.86. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to MUNCAPM.BO's ROE of +0.05%. Regarding short-term risk, BIOGEN.BO is less volatile compared to MUNCAPM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check MUNCAPM.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, NAYSAA.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while NAYSAA.BO trades at ₹307.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas NAYSAA.BO's P/E ratio is 379.26. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to NAYSAA.BO's ROE of +0.60%. Regarding short-term risk, BIOGEN.BO is less volatile compared to NAYSAA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check NAYSAA.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SWASTIKA.BO has a market cap of 1.1B. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SWASTIKA.BO trades at ₹54.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SWASTIKA.BO's P/E ratio is 76.80. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SWASTIKA.BO's ROE of +0.09%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SWASTIKA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SWASTIKA.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ASITCFIN.BO has a market cap of 989.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ASITCFIN.BO trades at ₹115.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ASITCFIN.BO's P/E ratio is -133.33. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ASITCFIN.BO's ROE of -0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ASITCFIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ASITCFIN.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ADVIKCA.BO has a market cap of 979.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ADVIKCA.BO trades at ₹1.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ADVIKCA.BO's P/E ratio is -4.35. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ADVIKCA.BO's ROE of -0.10%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ADVIKCA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ADVIKCA.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, TITANSEC.BO has a market cap of 901.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while TITANSEC.BO trades at ₹37.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas TITANSEC.BO's P/E ratio is 9.08. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to TITANSEC.BO's ROE of +0.10%. Regarding short-term risk, BIOGEN.BO is less volatile compared to TITANSEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check TITANSEC.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, MUKESHB.BO has a market cap of 878.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while MUKESHB.BO trades at ₹134.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas MUKESHB.BO's P/E ratio is 14.69. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to MUKESHB.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is more volatile compared to MUKESHB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check MUKESHB.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SAUMYA.BO has a market cap of 845.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SAUMYA.BO trades at ₹128.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SAUMYA.BO's P/E ratio is -24.68. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SAUMYA.BO's ROE of -0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SAUMYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SAUMYA.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, CHRTEDCA.BO has a market cap of 825.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while CHRTEDCA.BO trades at ₹274.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas CHRTEDCA.BO's P/E ratio is 12.31. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to CHRTEDCA.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to CHRTEDCA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check CHRTEDCA.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, VGCL.BO has a market cap of 755.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while VGCL.BO trades at ₹33.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas VGCL.BO's P/E ratio is -6.12. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to VGCL.BO's ROE of -0.08%. Regarding short-term risk, BIOGEN.BO is less volatile compared to VGCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check VGCL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, WALLFORT.BO has a market cap of 755.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while WALLFORT.BO trades at ₹78.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas WALLFORT.BO's P/E ratio is -6.89. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to WALLFORT.BO's ROE of -0.04%. Regarding short-term risk, BIOGEN.BO is more volatile compared to WALLFORT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check WALLFORT.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, GOGIACAP.BO has a market cap of 719M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while GOGIACAP.BO trades at ₹113.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas GOGIACAP.BO's P/E ratio is -2.98. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to GOGIACAP.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is more volatile compared to GOGIACAP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check GOGIACAP.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ISLCONSUL.BO has a market cap of 710.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ISLCONSUL.BO trades at ₹29.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ISLCONSUL.BO's P/E ratio is -84.57. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ISLCONSUL.BO's ROE of -0.06%. Regarding short-term risk, BIOGEN.BO is more volatile compared to ISLCONSUL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check ISLCONSUL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, GOWRALE.BO has a market cap of 688.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while GOWRALE.BO trades at ₹78.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas GOWRALE.BO's P/E ratio is 7.32. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to GOWRALE.BO's ROE of +0.20%. Regarding short-term risk, BIOGEN.BO is less volatile compared to GOWRALE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check GOWRALE.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, BAMPSL.BO has a market cap of 664.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while BAMPSL.BO trades at ₹19.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas BAMPSL.BO's P/E ratio is 33.66. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to BAMPSL.BO's ROE of +0.06%. Regarding short-term risk, BIOGEN.BO is less volatile compared to BAMPSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check BAMPSL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SKPSEC.BO has a market cap of 660.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SKPSEC.BO trades at ₹98.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SKPSEC.BO's P/E ratio is 6.88. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SKPSEC.BO's ROE of +0.19%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SKPSEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SKPSEC.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, BNRSEC.BO has a market cap of 659.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while BNRSEC.BO trades at ₹15.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas BNRSEC.BO's P/E ratio is -4.03. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to BNRSEC.BO's ROE of +0.08%. Regarding short-term risk, BIOGEN.BO is less volatile compared to BNRSEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check BNRSEC.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, HBPOR.BO has a market cap of 638.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while HBPOR.BO trades at ₹60.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas HBPOR.BO's P/E ratio is -78.03. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to HBPOR.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is less volatile compared to HBPOR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check HBPOR.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ELIXIR.BO has a market cap of 603M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ELIXIR.BO trades at ₹103.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ELIXIR.BO's P/E ratio is -63.35. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ELIXIR.BO's ROE of -0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ELIXIR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ELIXIR.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, MYMONEY.BO has a market cap of 593.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while MYMONEY.BO trades at ₹37.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas MYMONEY.BO's P/E ratio is -11.97. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to MYMONEY.BO's ROE of -0.18%. Regarding short-term risk, BIOGEN.BO is less volatile compared to MYMONEY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check MYMONEY.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, JOINDRE.BO has a market cap of 570.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while JOINDRE.BO trades at ₹41.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas JOINDRE.BO's P/E ratio is 7.06. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to JOINDRE.BO's ROE of +0.10%. Regarding short-term risk, BIOGEN.BO is more volatile compared to JOINDRE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check JOINDRE.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, LADDERUP.BO has a market cap of 567.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while LADDERUP.BO trades at ₹54.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas LADDERUP.BO's P/E ratio is 35.20. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to LADDERUP.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is more volatile compared to LADDERUP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check LADDERUP.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, MEAPL.BO has a market cap of 519.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while MEAPL.BO trades at ₹32.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas MEAPL.BO's P/E ratio is 29.50. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to MEAPL.BO's ROE of +0.19%. Regarding short-term risk, BIOGEN.BO is less volatile compared to MEAPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check MEAPL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, MEFCOMCAP.BO has a market cap of 519.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while MEFCOMCAP.BO trades at ₹11.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas MEFCOMCAP.BO's P/E ratio is -51.64. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to MEFCOMCAP.BO's ROE of -0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to MEFCOMCAP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check MEFCOMCAP.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SITAENT.BO has a market cap of 482.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SITAENT.BO trades at ₹154.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SITAENT.BO's P/E ratio is 9.20. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SITAENT.BO's ROE of +0.32%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SITAENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SITAENT.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SMIFS.BO has a market cap of 479.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SMIFS.BO trades at ₹81.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SMIFS.BO's P/E ratio is 41.44. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SMIFS.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SMIFS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SMIFS.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, INDUSFINL.BO has a market cap of 476.2M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while INDUSFINL.BO trades at ₹50.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas INDUSFINL.BO's P/E ratio is 75.63. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to INDUSFINL.BO's ROE of +0.03%. Regarding short-term risk, BIOGEN.BO is less volatile compared to INDUSFINL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check INDUSFINL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SAICAPI.BO has a market cap of 460.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SAICAPI.BO trades at ₹160.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SAICAPI.BO's P/E ratio is 3.33. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SAICAPI.BO's ROE of +0.04%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SAICAPI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SAICAPI.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SRESTHA.BO has a market cap of 442.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SRESTHA.BO trades at ₹0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SRESTHA.BO's P/E ratio is -0.36. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SRESTHA.BO's ROE of -0.36%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SRESTHA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SRESTHA.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, KIDUJA.BO has a market cap of 432M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while KIDUJA.BO trades at ₹18.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas KIDUJA.BO's P/E ratio is -19.15. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to KIDUJA.BO's ROE of +0.11%. Regarding short-term risk, BIOGEN.BO is more volatile compared to KIDUJA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check KIDUJA.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, NAM.BO has a market cap of 431.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while NAM.BO trades at ₹80.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas NAM.BO's P/E ratio is 181.82. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to NAM.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is less volatile compared to NAM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check NAM.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ANUPAM.BO has a market cap of 415.6M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ANUPAM.BO trades at ₹2.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ANUPAM.BO's P/E ratio is 24.33. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ANUPAM.BO's ROE of +0.06%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ANUPAM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ANUPAM.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ROYALIND.BO has a market cap of 403.5M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ROYALIND.BO trades at ₹3.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ROYALIND.BO's P/E ratio is 8.34. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ROYALIND.BO's ROE of +0.20%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ROYALIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ROYALIND.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, PANINDIAC.BO has a market cap of 370.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while PANINDIAC.BO trades at ₹1.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas PANINDIAC.BO's P/E ratio is -173.00. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to PANINDIAC.BO's ROE of -0.42%. Regarding short-term risk, BIOGEN.BO is less volatile compared to PANINDIAC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check PANINDIAC.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, BRIDGESE.BO has a market cap of 370M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while BRIDGESE.BO trades at ₹11.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas BRIDGESE.BO's P/E ratio is 71.56. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to BRIDGESE.BO's ROE of +0.22%. Regarding short-term risk, BIOGEN.BO is less volatile compared to BRIDGESE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check BRIDGESE.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, DHANCOT.BO has a market cap of 359.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while DHANCOT.BO trades at ₹70.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas DHANCOT.BO's P/E ratio is 111.92. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to DHANCOT.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is less volatile compared to DHANCOT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check DHANCOT.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SPCAPIT.BO has a market cap of 354.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SPCAPIT.BO trades at ₹58.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SPCAPIT.BO's P/E ratio is 5.60. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SPCAPIT.BO's ROE of +0.22%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SPCAPIT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SPCAPIT.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, AJCON.BO has a market cap of 349.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while AJCON.BO trades at ₹6.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas AJCON.BO's P/E ratio is -572.00. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to AJCON.BO's ROE of -0.00%. Regarding short-term risk, BIOGEN.BO is less volatile compared to AJCON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check AJCON.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SHRINIWAS.BO has a market cap of 339.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SHRINIWAS.BO trades at ₹10.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SHRINIWAS.BO's P/E ratio is N/A. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SHRINIWAS.BO's ROE of +0.19%. Regarding short-term risk, BIOGEN.BO is more volatile compared to SHRINIWAS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check SHRINIWAS.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, INDIANVSH.BO has a market cap of 317.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while INDIANVSH.BO trades at ₹8.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas INDIANVSH.BO's P/E ratio is -3.21. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to INDIANVSH.BO's ROE of +0.25%. Regarding short-term risk, BIOGEN.BO is less volatile compared to INDIANVSH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check INDIANVSH.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, GOLDLINE.BO has a market cap of 317.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while GOLDLINE.BO trades at ₹0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas GOLDLINE.BO's P/E ratio is 610.00. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to GOLDLINE.BO's ROE of +0.00%. Regarding short-term risk, BIOGEN.BO is less volatile compared to GOLDLINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check GOLDLINE.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, RAMSONS.BO has a market cap of 303.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while RAMSONS.BO trades at ₹106.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas RAMSONS.BO's P/E ratio is 3.95. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to RAMSONS.BO's ROE of +0.53%. Regarding short-term risk, BIOGEN.BO is more volatile compared to RAMSONS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check RAMSONS.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, BERVINL.BO has a market cap of 303.8M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while BERVINL.BO trades at ₹54.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas BERVINL.BO's P/E ratio is -1.85. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to BERVINL.BO's ROE of -0.75%. Regarding short-term risk, BIOGEN.BO is less volatile compared to BERVINL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check BERVINL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SUMEDHA.BO has a market cap of 303.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SUMEDHA.BO trades at ₹37.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SUMEDHA.BO's P/E ratio is 6.07. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SUMEDHA.BO's ROE of +0.08%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SUMEDHA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SUMEDHA.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, PURSHOTTAM.BO has a market cap of 300.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while PURSHOTTAM.BO trades at ₹38.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas PURSHOTTAM.BO's P/E ratio is 38.24. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to PURSHOTTAM.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to PURSHOTTAM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check PURSHOTTAM.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ARNOLD.BO has a market cap of 297.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ARNOLD.BO trades at ₹12.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ARNOLD.BO's P/E ratio is 11.81. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ARNOLD.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ARNOLD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARNOLD.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, VERTEX.BO has a market cap of 266.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while VERTEX.BO trades at ₹3.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas VERTEX.BO's P/E ratio is -17.14. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to VERTEX.BO's ROE of -0.15%. Regarding short-term risk, BIOGEN.BO is less volatile compared to VERTEX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check VERTEX.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, ARUNIS.BO has a market cap of 265.3M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while ARUNIS.BO trades at ₹90.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas ARUNIS.BO's P/E ratio is 51.71. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to ARUNIS.BO's ROE of +0.48%. Regarding short-term risk, BIOGEN.BO is less volatile compared to ARUNIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check ARUNIS.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, GALACTICO.BO has a market cap of 262M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while GALACTICO.BO trades at ₹1.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas GALACTICO.BO's P/E ratio is 7.48. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to GALACTICO.BO's ROE of +0.06%. Regarding short-term risk, BIOGEN.BO is less volatile compared to GALACTICO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check GALACTICO.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, NDASEC.BO has a market cap of 254.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while NDASEC.BO trades at ₹38.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas NDASEC.BO's P/E ratio is 178.21. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to NDASEC.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to NDASEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check NDASEC.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, STANROS.BO has a market cap of 250M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while STANROS.BO trades at ₹61.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas STANROS.BO's P/E ratio is -8.29. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to STANROS.BO's ROE of -0.07%. Regarding short-term risk, BIOGEN.BO is less volatile compared to STANROS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check STANROS.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SULABEN.BO has a market cap of 234.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SULABEN.BO trades at ₹2.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SULABEN.BO's P/E ratio is 10.59. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SULABEN.BO's ROE of +0.07%. Regarding short-term risk, BIOGEN.BO is less volatile compared to SULABEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SULABEN.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, GSBFIN.BO has a market cap of 228M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while GSBFIN.BO trades at ₹35.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas GSBFIN.BO's P/E ratio is -211.11. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to GSBFIN.BO's ROE of -0.01%. Regarding short-term risk, BIOGEN.BO is more volatile compared to GSBFIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check GSBFIN.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, KJMCFIN.BO has a market cap of 225M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while KJMCFIN.BO trades at ₹46.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas KJMCFIN.BO's P/E ratio is 17.54. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to KJMCFIN.BO's ROE of +0.01%. Regarding short-term risk, BIOGEN.BO is less volatile compared to KJMCFIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check KJMCFIN.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, RFSL.BO has a market cap of 224.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while RFSL.BO trades at ₹30.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas RFSL.BO's P/E ratio is 44.09. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to RFSL.BO's ROE of +0.06%. Regarding short-term risk, BIOGEN.BO is more volatile compared to RFSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check RFSL.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, KJMCCORP.BO has a market cap of 217.1M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while KJMCCORP.BO trades at ₹51.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas KJMCCORP.BO's P/E ratio is 19.67. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to KJMCCORP.BO's ROE of +0.02%. Regarding short-term risk, BIOGEN.BO is less volatile compared to KJMCCORP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check KJMCCORP.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, STEP2COR.BO has a market cap of 214.4M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while STEP2COR.BO trades at ₹29.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas STEP2COR.BO's P/E ratio is 6.71. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to STEP2COR.BO's ROE of +0.25%. Regarding short-term risk, BIOGEN.BO is less volatile compared to STEP2COR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check STEP2COR.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, HELPAGE.BO has a market cap of 208.9M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while HELPAGE.BO trades at ₹21.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas HELPAGE.BO's P/E ratio is 7.69. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to HELPAGE.BO's ROE of +0.16%. Regarding short-term risk, BIOGEN.BO is less volatile compared to HELPAGE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check HELPAGE.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, CILSEC.BO has a market cap of 208M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while CILSEC.BO trades at ₹39.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas CILSEC.BO's P/E ratio is 10.69. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to CILSEC.BO's ROE of +0.06%. Regarding short-term risk, BIOGEN.BO is more volatile compared to CILSEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOGEN.BO.Check CILSEC.BO's competition here

BIOGEN.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BIOGEN.BO stands at 613.8M. In comparison, SICAPIT.BO has a market cap of 200.7M. Regarding current trading prices, BIOGEN.BO is priced at ₹0.67, while SICAPIT.BO trades at ₹39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BIOGEN.BO currently has a P/E ratio of 22.67, whereas SICAPIT.BO's P/E ratio is N/A. In terms of profitability, BIOGEN.BO's ROE is +0.03%, compared to SICAPIT.BO's ROE of N/A. Regarding short-term risk, BIOGEN.BO is less volatile compared to SICAPIT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGEN.BO.Check SICAPIT.BO's competition here